Sialidosis: Current Treatment Options and Symptom Management Strategies
Disease Overview
Sialidosis (neuraminidase deficiency) is an autosomal recessive lysosomal storage disorder caused by NEU1 mutations. Deficient sialidase leads to accumulation of sialylated oligosaccharides/glycoproteins. Two phenotypes: Type I (milder, adolescent onset, cherry-red spot, myoclonus) and Type II (severe, infantile, dysmorphism, organomegaly, developmental regression).
Current Management (No Cure)
- Symptomatic care: Anticonvulsants for myoclonus/seizures; physical/occupational therapy for mobility; speech/swallowing therapy.
- Respiratory support: For recurrent aspiration or restrictive lung disease.
- Enzyme replacement therapy (ERT): Investigational; recombinant human NEU1 has shown substrate reduction in models; clinical trials ongoing.
- Substrate reduction therapy: Not yet established.
- Gene therapy: AAV-NEU1 vectors in preclinical/early clinical stages.
- Hematopoietic stem cell transplant (HSCT): Limited experience; may stabilize neurocognitive decline in Type II if done early.
Multidisciplinary Care
Genetics, neurology, pulmonology, orthopedics, ophthalmology, palliative care. Genetic counseling for family.
Prognosis
Type I: near-normal lifespan with disability. Type II: life-limiting, often childhood mortality. Research into disease-modifying therapies is active.
Bulimia - Related Articles
- Buccal Fat Removal (Buccal Lipectomy): Procedure & Results
- Burnt-Tasting Burps: Causes from Acid Reflux to Serious Conditions
- Bulimia Screening Questionnaire: Identifying Potential Symptoms
- Bulimia vs. Anorexia Nervosa: Understanding the Risk Comparison
- Hot Tub and Sauna Safety During Pregnancy: What You Need to Know
- Bulimia Prevalence: Countries with Higher Rates - A Comprehensive Overview
- Elton John's Eating Disorder: Anorexia Nervosa, Not Bulimia
